TAK vs. VEEV: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at TAK and VEEV, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
TAK trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, VEEV is a standard domestic listing.
| Symbol | TAK | VEEV |
|---|---|---|
| Company Name | Takeda Pharmaceutical Company Limited | Veeva Systems Inc. |
| Country | Japan | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Pharmaceuticals | Health Care Technology |
| Market Capitalization | 46.76 billion USD | 48.07 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | January 5, 2010 | October 16, 2013 |
| Security Type | ADR | Common Stock |
Historical Performance
This chart compares the performance of TAK and VEEV by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | TAK | VEEV |
|---|---|---|
| 5-Day Price Return | -3.16% | 7.19% |
| 13-Week Price Return | -0.96% | 3.45% |
| 26-Week Price Return | -4.96% | 26.44% |
| 52-Week Price Return | 5.51% | 41.29% |
| Month-to-Date Return | -2.40% | 10.66% |
| Year-to-Date Return | 3.21% | 41.69% |
| 10-Day Avg. Volume | 4.99M | 1.29M |
| 3-Month Avg. Volume | 4.26M | 1.44M |
| 3-Month Volatility | 18.65% | 26.99% |
| Beta | 0.38 | 0.98 |
Profitability
Return on Equity (TTM)
TAK
1.95%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.85%
- Q1
- 5.40%
- Min
- -10.91%
TAK’s Return on Equity of 1.95% is in the lower quartile for the Pharmaceuticals industry. This indicates a less efficient generation of profit from its equity base when compared to its competitors.
VEEV
13.40%
Health Care Technology Industry
- Max
- 48.09%
- Q3
- 41.80%
- Median
- 18.17%
- Q1
- 11.64%
- Min
- 11.05%
VEEV’s Return on Equity of 13.40% is on par with the norm for the Health Care Technology industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
TAK
3.06%
Pharmaceuticals Industry
- Max
- 40.67%
- Q3
- 19.07%
- Median
- 12.31%
- Q1
- 4.50%
- Min
- -9.91%
Falling into the lower quartile for the Pharmaceuticals industry, TAK’s Net Profit Margin of 3.06% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.
VEEV
27.29%
Health Care Technology Industry
- Max
- 52.24%
- Q3
- 49.15%
- Median
- 33.59%
- Q1
- 16.86%
- Min
- 13.38%
VEEV’s Net Profit Margin of 27.29% is aligned with the median group of its peers in the Health Care Technology industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
TAK
8.05%
Pharmaceuticals Industry
- Max
- 45.78%
- Q3
- 23.14%
- Median
- 16.68%
- Q1
- 7.98%
- Min
- -7.13%
TAK’s Operating Profit Margin of 8.05% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
VEEV
26.93%
Health Care Technology Industry
- Max
- 74.05%
- Q3
- 65.56%
- Median
- 33.50%
- Q1
- 22.83%
- Min
- 21.46%
VEEV’s Operating Profit Margin of 26.93% is around the midpoint for the Health Care Technology industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | TAK | VEEV |
|---|---|---|
| Return on Equity (TTM) | 1.95% | 13.40% |
| Return on Assets (TTM) | 0.95% | 10.96% |
| Net Profit Margin (TTM) | 3.06% | 27.29% |
| Operating Profit Margin (TTM) | 8.05% | 26.93% |
| Gross Profit Margin (TTM) | 64.78% | 75.59% |
Financial Strength
Current Ratio (MRQ)
TAK
1.16
Pharmaceuticals Industry
- Max
- 4.65
- Q3
- 2.64
- Median
- 1.85
- Q1
- 1.26
- Min
- 0.78
TAK’s Current Ratio of 1.16 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
VEEV
5.57
Health Care Technology Industry
- Max
- 6.49
- Q3
- 6.49
- Median
- 6.02
- Q1
- 3.62
- Min
- 2.96
VEEV’s Current Ratio of 5.57 aligns with the median group of the Health Care Technology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
TAK
0.66
Pharmaceuticals Industry
- Max
- 1.75
- Q3
- 0.82
- Median
- 0.35
- Q1
- 0.13
- Min
- 0.00
TAK’s Debt-to-Equity Ratio of 0.66 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
VEEV
0.00
Health Care Technology Industry
- Max
- 0.14
- Q3
- 0.10
- Median
- 0.01
- Q1
- 0.00
- Min
- 0.00
Falling into the lower quartile for the Health Care Technology industry, VEEV’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio (TTM)
TAK
1.96
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 9.83
- Q1
- 2.37
- Min
- -42.71
In the lower quartile for the Pharmaceuticals industry, TAK’s Interest Coverage Ratio of 1.96 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.
VEEV
169.00
Health Care Technology Industry
- Max
- 224.12
- Q3
- 224.12
- Median
- 219.00
- Q1
- 219.00
- Min
- 219.00
VEEV’s Interest Coverage Ratio of 169.00 is below the typical range for the Health Care Technology industry. This suggests a weaker ability to meet debt obligations compared to its peers and may indicate a higher level of financial risk.
Financial Strength at a Glance
| Symbol | TAK | VEEV |
|---|---|---|
| Current Ratio (MRQ) | 1.16 | 5.57 |
| Quick Ratio (MRQ) | 0.59 | 5.48 |
| Debt-to-Equity Ratio (MRQ) | 0.66 | 0.00 |
| Interest Coverage Ratio (TTM) | 1.96 | 169.00 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
TAK
4.53%
Pharmaceuticals Industry
- Max
- 7.14%
- Q3
- 3.45%
- Median
- 2.17%
- Q1
- 0.33%
- Min
- 0.00%
With a Dividend Yield of 4.53%, TAK offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
VEEV
0.00%
Health Care Technology Industry
- Max
- 0.89%
- Q3
- 0.70%
- Median
- 0.15%
- Q1
- 0.04%
- Min
- 0.00%
VEEV currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
TAK
124.94%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 97.17%
- Median
- 53.47%
- Q1
- 22.97%
- Min
- 0.00%
TAK’s Dividend Payout Ratio of 124.94% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
VEEV
0.00%
Health Care Technology Industry
- Max
- 101.92%
- Q3
- 87.10%
- Median
- 42.63%
- Q1
- 10.66%
- Min
- 0.00%
VEEV has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | TAK | VEEV |
|---|---|---|
| Dividend Yield (TTM) | 4.53% | 0.00% |
| Dividend Payout Ratio (TTM) | 124.94% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
TAK
49.95
Pharmaceuticals Industry
- Max
- 45.19
- Q3
- 27.91
- Median
- 20.59
- Q1
- 15.08
- Min
- 3.79
At 49.95, TAK’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Pharmaceuticals industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
VEEV
59.31
Health Care Technology Industry
- Max
- 280.41
- Q3
- 225.12
- Median
- 59.01
- Q1
- 44.08
- Min
- 39.20
VEEV’s P/E Ratio of 59.31 is within the middle range for the Health Care Technology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
TAK
1.53
Pharmaceuticals Industry
- Max
- 8.87
- Q3
- 4.56
- Median
- 2.14
- Q1
- 1.58
- Min
- 0.11
In the lower quartile for the Pharmaceuticals industry, TAK’s P/S Ratio of 1.53 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
VEEV
16.18
Health Care Technology Industry
- Max
- 146.49
- Q3
- 115.78
- Median
- 19.83
- Q1
- 7.94
- Min
- 5.25
VEEV’s P/S Ratio of 16.18 aligns with the market consensus for the Health Care Technology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
TAK
1.03
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.99
- Median
- 2.48
- Q1
- 1.53
- Min
- 0.59
TAK’s P/B Ratio of 1.03 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
VEEV
7.00
Health Care Technology Industry
- Max
- 115.01
- Q3
- 89.07
- Median
- 9.11
- Q1
- 4.04
- Min
- 3.06
VEEV’s P/B Ratio of 7.00 is within the conventional range for the Health Care Technology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | TAK | VEEV |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 49.95 | 59.31 |
| Price-to-Sales Ratio (TTM) | 1.53 | 16.18 |
| Price-to-Book Ratio (MRQ) | 1.03 | 7.00 |
| Price-to-Free Cash Flow Ratio (TTM) | 8.36 | 36.17 |